In the study, the researchers studied the role that the IDH mutation may have in the grading and mitotic index in grade II–III diffuse astrocytomas, and their results demonstrated that the IDH mutation determines the effect of mitotic index on patient outcome (37, 38). This evidence concerns the gene IDH2 and diffuse astrocytoma.